Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer
October 2021
in “Exploration of targeted anti-tumor therapy”
TLDR Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.
Adjuvant hormonal therapy for hormone-receptor-positive breast cancer often results in hair loss similar to female androgenic alopecia, known as oncotherapy-induced alopecia. This hair loss, while not severe, significantly affects patients' quality of life. It is caused by the therapy's inhibition of estrogenic activity, which increases dehydrotestosterone (DHT) levels around hair follicles, shortening the hair growth phase and altering hair texture. The authors recommend against using topical hormones to treat this hair loss due to potential oncogenic effects. Instead, they suggest a treatment approach using topical formulations containing minoxidil 2%, cetirizine 0.5%, and hydrocortisone butyrate in alcohol, applied daily during the hormonal therapy. For more severe cases, or if previous female androgenic alopecia was present, a formulation of minoxidil 5% and hydrocortisone butyrate 0.1% is recommended.
View this study on explorationpub.com →
Cited in this study
research Prevention and Treatment of Chemotherapy-Induced Alopecia
Scalp cooling can help prevent hair loss from chemotherapy, but treatment should be tailored to the individual and more research is needed.
research Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer
Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.
research A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia
Topical cetirizine improves hair density and thickness in androgenetic alopecia, but more research is needed.
research Multi-therapies in androgenetic alopecia: review and clinical experiences
Multiple treatments work best for hair loss.
research Long‐term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy‐induced eyelash hypotrichosis: a randomized controlled trial
Bimatoprost solution is effective and safe for long-term use in treating eyelash thinning.
research Increased DHT levels in androgenic alopecia have been selected for to protect men from prostate cancer
Higher DHT in male baldness may protect against prostate cancer.
research Pattern Alopecia during Hormonal Anticancer Therapy in Patients with Breast Cancer
Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.
research Alopecia With Endocrine Therapies in Patients With Cancer
Endocrine therapies for cancer significantly increase the risk of hair loss.
research Aromatase inhibitors induce ‘male pattern hair loss’ in women?
Aromatase inhibitors cause male pattern hair loss in women.
research Female pattern hair loss possibly caused by tamoxifen: Androgen receptor expression in the outer root sheath in the affected area
Tamoxifen may cause female hair loss by increasing androgen receptor expression.
research Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss
Aromatase gene variation may increase female hair loss risk.
research The Hair Follicle as an Estrogen Target and Source
Estrogens significantly influence hair growth by interacting with receptors in hair follicles and may help regulate the hair growth cycle.
research Androgenetic Alopecia in Women
Androgenetic alopecia in women needs more research and better management strategies.
research Tamoxifen-Induced Total Alopecia
research Tamoxifen-Induced Female Androgenetic Alopecia in a Patient with Breast Cancer
Tamoxifen caused hair loss in a 52-year-old woman.